专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0012139B1 HYPOXIA REGULATED GENES 审中-公开
标题翻译： HYPOXIA调节基因
公开(公告)号：WO0012139B1
公开(公告)日：2000-05-04
申请号：PCT/US9920393
申请日：1999-08-27
申请人： QUARK BIOTECH INC , KOHN KENNETH , FEINSTEIN ELENA , EINAT PAZ , SKALITER RAMI
发明人： FEINSTEIN ELENA , EINAT PAZ , SKALITER RAMI
IPC分类号： G01N33/53 , A61K31/711 , A61K38/00 , A61K45/00 , A61K48/00 , A61P9/00 , A61P9/10 , A61P11/00 , A61P35/00 , A61P43/00 , C07K14/47 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/566 , G01N33/58 , G01N33/68 , G01N37/00 , C07H21/04
CPC分类号： C07K14/47 , A61K38/00 , A61K48/00
摘要： There is provided the polynucleotide sequence of a gene whose expression is modulated by hypoxic conditions. Also provided is a polynucleotide sequence encoding a gene for protein 2-2-83. A pharmaceutical composition for modulating hypoxia and ischemia having an effective amount of a polynucleotide or protein having the nucleic acid sequence according to SEQ. ID NO. 1 and 2 or a functional analog thereof and a pharmaceutically acceptable carrier is also provided. There is provided a method of regulating hypoxic associated pathologies and tumorigenesis by administering an effective amount of a polynucleotide, proteins direct or indirect biologically active product of enzymatic activity of the protein, or inhibitors of direct or indirect biologically active product of enzymatic activity of the protein having a nucleic acid sequence from at least one from the group containing SEQ. ID NO. 1 and 2 and functional analogs thereof and a pharmaceutically acceptable carrier. A method of regulating hypoxic associated pathologies and tumorigenesis by inhibiting the enzymatic activity of the protein encoded by the polynucleotide sequences from at least one from the group containing SEQ ID NO. 1 and 2 and functional analogs thereof is provided. A hypoxia response regulating is further provided. Neuroprotective and neurotrophic agents comprising a gene product of the polynucleotide sequence of 2-2-83 according to SEQ. ID NO. 1 and 2 and functional analogs thereof is also provided. There is provided a method of diagnosing the presence of a hypoxia associated pathology or tumorigenesis by screening for the reduced expression of the gene encoded by the nucleic acid sequence according to SEQ. ID NO. 1 and 2 and functional analogs thereof.
摘要翻译：提供了表达由缺氧条件调节的基因的多核苷酸序列。还提供了编码蛋白质2-2-83的基因的多核苷酸序列。用于调节缺氧和缺血的药物组合物，其具有有效量的具有根据SEQ ID NO：1的核酸序列的多核苷酸或蛋白质。证件号码。还提供了1和2或其功能类似物和药学上可接受的载体。提供了一种通过施用有效量的多核苷酸，蛋白质的酶活性的直接或间接生物活性产物或蛋白质的酶活性的直接或间接生物活性产物的抑制剂来调节缺氧相关病理和肿瘤发生的方法具有至少一个含有SEQ ID NO：1的基团的核酸序列。证件号码。 1和2及其功能类似物和药学上可接受的载体。一种通过抑制由多核苷酸序列编码的蛋白质的酶活性调节缺氧相关病理和肿瘤发生的方法，所述多核苷酸序列至少含有SEQ ID NO： 1和2及其功能类似物。进一步提供缺氧反应调节。神经保护剂和神经营养剂，其包含根据SEQ ID NO：2-2-83的多核苷酸序列的基因产物。证件号码。还提供了1和2及其功能类似物。提供了通过筛选由根据SEQ ID NO：1的核酸序列编码的基因的降低的表达来诊断缺氧相关病理学或肿瘤发生的存在的方法。证件号码。 1和2及其功能类似物。

2. 发明申请

WO0246364A8 GENES ASSOCIATED WITH MECHANICAL STRESS, EXPRESSION PRODUCTS THEREFROM, AND USES THEREOF 审中-公开
标题翻译：与机械应力相关的基因，其表达产物及其用途
公开(公告)号：WO0246364A8
公开(公告)日：2004-01-15
申请号：PCT/US0146400
申请日：2001-12-04
申请人： QUARK BIOTECH INC , EINAT PAZ , SEGEV ORIT , SKALITER RAMI , FEINSTEIN ELENA , FAERMAN ALEXANDER , SAMACH AVIVA
发明人： EINAT PAZ , SEGEV ORIT , SKALITER RAMI , FEINSTEIN ELENA , FAERMAN ALEXANDER , SAMACH AVIVA
IPC分类号： C12N15/09 , A61K31/7088 , A61K38/00 , A61K39/395 , A61K48/00 , A61P1/02 , A61P19/08 , A61P19/10 , C07K14/47 , C07K14/51 , C07K14/705 , C07K16/18 , C12N15/12 , C12P21/02 , C12Q1/68 , C07H21/02 , A01N37/18 , A01N43/40 , A61K31/70 , C07H21/04 , C07K1/00 , C07K14/00 , C07K16/00 , C07K17/00
CPC分类号： C07K14/47 , A61K48/00 , C07K14/51 , C12Q1/6883 , C12Q2600/158

3. 发明申请

WO0246364A9 GENES ASSOCIATED WITH MECHANICAL STRESS, EXPRESSION PRODUCTS THEREFROM, AND USES THEREOF 审中-公开
标题翻译：与机械应力相关的基因，其表达产物及其用途
公开(公告)号：WO0246364A9
公开(公告)日：2003-01-23
申请号：PCT/US0146400
申请日：2001-12-04
申请人： QUARK BIOTECH INC , EINAT PAZ , SEGEV ORIT , SKALITER RAMI , FEINSTEIN ELENA , FAERMAN ALEXANDER , SAMACH AVIVA
发明人： EINAT PAZ , SEGEV ORIT , SKALITER RAMI , FEINSTEIN ELENA , FAERMAN ALEXANDER , SAMACH AVIVA
IPC分类号： C12N15/09 , A61K31/7088 , A61K38/00 , A61K39/395 , A61K48/00 , A61P1/02 , A61P19/08 , A61P19/10 , C07K14/47 , C07K14/51 , C07K14/705 , C07K16/18 , C12N15/12 , C12P21/02 , C12Q1/68 , C12N
CPC分类号： C07K14/47 , A61K48/00 , C07K14/51 , C12Q1/6883 , C12Q2600/158
摘要： The disclosure relates to mechanical stress induced genes, and functional equivalents, such as those from humans and from mice, probes therefor, tests to identify such genes, expression products of such genes, uses for such genes and expression products, e.g., in diagnosis (for instance risk determination), treatment, prevention, or control, of osteoporosis or factors or processes which lead to osteoporosis; and, to diagnostic, treatment, prevention, or control methods or processes, as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors.
摘要翻译：本公开涉及机械应激诱导的基因和功能等同物，例如来自人和小鼠的那些，其探针，用于鉴定这些基因的测试，这些基因的表达产物，这些基因和表达产物的用途，例如在诊断（例如风险确定），治疗，预防或控制骨质疏松症或导致骨质疏松症的因素或过程; 以及诊断，治疗，预防或控制方法或过程，以及其组合物以及用于制备和使用这些组合物及其受体的方法或方法以及用于获得和使用这些受体的方法或方法。

4. 发明申请

WO0122864A9 SEQUENCES CHARACTERISTIC OF BLADDER CANCER 审中-公开
标题翻译：乳腺癌的序列特征
公开(公告)号：WO0122864A9
公开(公告)日：2002-12-12
申请号：PCT/US0041005
申请日：2000-09-27
申请人： QUARK BIOTECH INC , FEINSTEIN ELENA , MOR ORNA , KOHN KENNETH I
发明人： FEINSTEIN ELENA , MOR ORNA
IPC分类号： C12P21/08 , C12Q1/68 , A61K31/70 , A61K38/00 , A61K39/395 , C07H21/02 , C07H21/04 , C07K16/00 , C12N15/63
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering to a patient a therapeutically effective amount of a ribozyme, antisense olignucleotide, or agonist against the nucleic acids sequences of the present invention are alos provided.
摘要翻译：提供了一种通过分析来自患者的组织样品中至少一种表达基因的存在来诊断患者膀胱癌的存在的方法，其中所表达的基因的存在指示膀胱癌。本发明还提供了表达膀胱癌的多核苷酸序列。还提供了膀胱癌的标记物。还提供了通过筛选至少一种表达基因的存在来诊断膀胱癌的方法，其中表达的基因的存在指示膀胱癌。通过向患者施用治疗有效量的针对本发明的核酸序列的核酶，反义寡核苷酸或激动剂来治疗和调节膀胱癌相关病理学的方法是提供的。

5. 发明申请

WO0122864A2 SEQUENCES CHARACTERISTIC OF BLADDER CANCER 审中-公开
标题翻译：膀胱癌的序列特征
公开(公告)号：WO0122864A2
公开(公告)日：2001-04-05
申请号：PCT/US0041005
申请日：2000-09-27
申请人： QUARK BIOTECH INC , KOHN KENNETH I , FEINSTEIN ELENA , MOR ORNA
发明人： FEINSTEIN ELENA , MOR ORNA
IPC分类号： C12P21/08 , C12Q1/68 , A61B
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering to a patient a therapeutically effective amount of a ribozyme, antisense olignucleotide, or agonist against the nucleic acids sequences of the present invention are alos provided.
摘要翻译：提供了通过分析来自患者的组织样品中至少一种表达基因的存在来诊断患者中膀胱癌的存在的方法，其中表达基因的存在指示膀胱癌。本发明还提供了其表达指示膀胱癌的多核苷酸序列。还提供了膀胱癌的标记。还提供了通过筛选至少一种表达基因的存在来诊断膀胱癌的方法，其中表达基因的存在指示膀胱癌。提供了通过向患者施用治疗有效量的核酶，反义寡核苷酸或针对本发明的核酸序列的激动剂来治疗和调节膀胱癌相关病理的方法。

6. 发明申请

WO2009116037A3 NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801 审中-公开
标题翻译：用于抑制RTP801的新型siRNA化合物
公开(公告)号：WO2009116037A3
公开(公告)日：2010-03-11
申请号：PCT/IL2009000302
申请日：2009-03-17
申请人： QUARK PHARMACEUTICALS INC , FEINSTEIN ELENA , SKALITER RAMI , KALINSKI HAGAR , METT IGOR
发明人： FEINSTEIN ELENA , SKALITER RAMI , KALINSKI HAGAR , METT IGOR
IPC分类号： A61K48/00
CPC分类号： C12N15/113 , C12N2310/14 , C12N2320/31
摘要： The present invention provides chemically modified siRNA compounds that target RTP801 and pharmaceutical compositions comprising same useful for treating microvascular disorders, eye diseases, hearing impairment, neurodegenerative diseases and disorders, spinal cord injury and respiratory conditions.
摘要翻译：本发明提供了靶向RTP801的化学修饰的siRNA化合物和包含用于治疗微血管病症，眼睛疾病，听觉障碍，神经变性疾病和病症，脊髓损伤和呼吸病症的药物组合物。

7. 发明申请

WO2008050329A2 NOVEL SIRNAS AND METHODS OF USE THEREOF 审中-公开
标题翻译：新颖的SIRNAS及其使用方法
公开(公告)号：WO2008050329A2
公开(公告)日：2008-05-02
申请号：PCT/IL2007001278
申请日：2007-10-25
申请人： QUARK PHARMACEUTICALS INC , FEINSTEIN ELENA , METT IGOR , SKALITER RAMI , KALINSKI HAGAR , IDELSON GREGORY HIRSH
发明人： FEINSTEIN ELENA , METT IGOR , SKALITER RAMI , KALINSKI HAGAR , IDELSON GREGORY HIRSH
IPC分类号： A61K31/70 , C12N15/113
CPC分类号： A61K31/70 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/343 , C12N2310/3521
摘要： The invention relates to compounds, in particular siRNAs, which inhibit the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions comprising administering to a subject in need of treatment for such disease or condition and/or symptom the compound or the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject. The invention also provides antibodies which inhibit specified human polypeptides and pharmaceutical compositions comprising one or more such antibodies.
摘要翻译：本发明涉及抑制特异性人基因表达的化合物，特别是siRNA。本发明还涉及包含这些化合物和药学上可接受的载体的药物组合物。本发明还提供了治疗和/或预防与这些疾病或病症相关的基因和/或症状相关的各种疾病或病症的发生率或严重程度的方法，包括向需要治疗的受试者施用此类疾病或病症和/或治疗有效剂量的化合物或药物组合物的症状，从而治疗受试者。本发明还提供抑制特定人多肽的抗体和包含一种或多种此类抗体的药物组合物。

8. 发明申请

WO2009044392A3 NOVEL SIRNA STRUCTURES 审中-公开
标题翻译：新的SIRNA结构
公开(公告)号：WO2009044392A3
公开(公告)日：2010-03-04
申请号：PCT/IL2008001197
申请日：2008-09-04
申请人： QUARK PHARMACEUTICALS INC , FEINSTEIN ELENA , AYGUN HUSEYIN , SKALITER RAMI , KALINSKI HAGAR , METT IGOR , MCSWIGGEN JAMES , BEIGELMAN LEONID
发明人： FEINSTEIN ELENA , AYGUN HUSEYIN , SKALITER RAMI , KALINSKI HAGAR , METT IGOR , MCSWIGGEN JAMES , BEIGELMAN LEONID
IPC分类号： A61K31/7088 , C07H21/02
CPC分类号： C07H21/02 , C12N15/111 , C12N2310/14 , C12N2310/319 , C12N2310/321 , C12N2310/3231 , C12N2310/332 , C12N2310/346 , C12N2320/51 , C12N2310/3521
摘要： The invention relates to siRNA compounds possessing novel sequences and structural motifs which down-regulate the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions comprising administering to a subject in need of treatment for such disease or condition and/or symptom the compound or the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.
摘要翻译：本发明涉及具有下调特定人基因表达的新型序列和结构基序的siRNA化合物。本发明还涉及包含这些化合物和药学上可接受的载体的药物组合物。本发明还提供了治疗和/或预防与这些疾病或病症相关的基因和/或症状相关的各种疾病或病症的发生率或严重性的方法，包括对需要治疗的疾病或病症和/或以治疗有效剂量症状化合物或药物组合物，从而治疗受试者。

9. 发明申请

WO2004100759A3 ENDO 180 RECEPTOR FOR DIAGNOSIS AND TREATMENT 审中-公开
标题翻译：第180号接受诊断和治疗的受试者
公开(公告)号：WO2004100759A3
公开(公告)日：2009-03-12
申请号：PCT/IL2004000423
申请日：2004-05-18
申请人： QUARK BIOTECH INC , MOR ORNA , FEINSTEIN ELENA , FAERMAN ALEXANDER
发明人： MOR ORNA , FEINSTEIN ELENA , FAERMAN ALEXANDER
IPC分类号： G01N33/53 , A61B20060101 , C07H21/04 , C12P21/06 , G01N33/50 , G01N33/68
CPC分类号： G01N33/5032 , G01N33/6872 , G01N2333/4724 , G01N2333/78
摘要： This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of a compound, and determining whether the binding of the ENDO180 receptor to the interactor is affected by the compound. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis. This application also relates to the use of ENDO 180 modulators in treatment of disease.
摘要翻译：本申请涉及鉴定能够调节人ENDO180受体活性的化合物的方法，该方法包括以下步骤：在不存在或存在下测量ENDO180受体与ENDO180受体在体内特异性相互作用的相互作用因子的结合的化合物，并确定ENDO180受体与相互作用体的结合是否受化合物的影响。本申请还涉及通过该方法鉴定的化合物在制备用于治疗疾病，特别是纤维化的药物中的用途。本申请还涉及使用ENDO 180调节剂治疗疾病。

10. 发明申请

WO2006131925A3 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES 审中-公开
标题翻译：用于治疗纤维性疾病和其他疾病的低分子化合物及其使用方法
公开(公告)号：WO2006131925A3
公开(公告)日：2007-08-02
申请号：PCT/IL2006000671
申请日：2006-06-08
申请人： QUARK BIOTECH INC , MOR ORNA , FEINSTEIN ELENA
发明人： MOR ORNA , FEINSTEIN ELENA
IPC分类号： C07H21/04 , A01N43/04 , A61K31/70 , A61K49/04 , C12P21/06 , C12Q1/68
CPC分类号： C12N15/1137 , C12N2310/14 , C12Y203/02013
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a gene of the TGase family at post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from fibrotic disease such as kidney and liver fibrosis and ocular scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective amount so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGase polypeptides.
摘要翻译：本发明涉及在转录后水平下调TGase家族基因表达的双链化合物，优选寡核糖核苷酸。本发明还涉及包含该化合物或能够表达寡核糖核苷酸的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肾脏和肝纤维化和眼瘢痕的患者的方法，其包括以治疗有效量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用对TGase多肽的抗体来治疗纤维化和其它疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式